Recent News

Astia Portfolio Company Alydia Health Acquired by Merck


KENILWORTH, N.J. & MENLO PARK, Calif.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Alydia Health announced today that they have entered into a definitive agreement pursuant to which, after the intended Merck spinoff of Organon, Organon will acquire Alydia Health. Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding. PPH is one of the most common complications of birth, resulting in pharmacologic treatment in up to 10% of mothers and potentially resulting in emergency intervention such as hysterectomy and blood transfusions, and, in some cases, maternal death.1 The transaction is expected to close after Organon has spun off from Merck as a standalone publicly traded company.


Sharon Vosmek included in UKTN's "The most powerful female VCs in UK tech"


Sharon Vosmek included in UKTN's "The most powerful female VCs in UK tech":


Astia Managing Director Angela Holter and Astia Fund featured in Shifter Norway


Norway-based Astia Managing Director Angela Holter talks about Astia's thesis and our Astia Fund in a recent piece in Shift Norway.


Astia Fund selected to the ImpactAssets 50 2021


Astia is excited to announce that Astia Fund has been selected to the ImpactAssets 50 2021! The #IA50 recognizes a diverse group of impact investment fund managers who demonstrate a commitment to generating positive social, environmental and financial impact.


Astia CEO Sharon Vosmek discussed the Astia Fund with Caroline Hyde, Romaine Bostick & Taylor Riggs on Bloomberg The Close


Caroline Hyde, Romaine Bostick & Taylor Riggs bring you the latest news and analysis leading up to the final minutes and seconds before the closing bell on Wall Street and tackle Tesla's investment in Bitcoin, the Palantir-IBM partnership and stimulus Guests Today: Joe Davis of Vanguard, Alexandre De Juniac of IATA, Melda Mergen of Columbia Threadneedle Investments, Mike Novogratz of Galaxy Digital, Kristina Hooper of Invesco, Sharon Vosmek of Astia. (Source: Bloomberg)


Astia Launches $100M Fund


NEW YORK, SAN FRANCISCO, LONDON, 08 February 2021: Astia, the Silicon Valley-headquartered organization dedicated to leveling the investment playing field - and redefining the traditional venture capital landscape - has launched a $100M early-stage venture fund aimed at addressing the extraordinary disparity in funding for companies that include women in founding or executive roles.

Led by an investment from Mastercard, the Astia Fund will invest globally in high-growth companies that have at least one woman in an executive, equity-holding position. Additional investors include: Priya Mathur, past president of the board of CalPERS; Jim O’Neill former chief economist and former chairman of Asset Management at Goldman Sachs; Farvatn Venture; Portola Creek Capital; Tides Foundation; numerous members of Toniic, a global network of impact investors; and other notable LPs.


Black-owned, Education-first Kids and Family Banking App Goalsetter raises $3.9M Seed Round led by Astia


Brooklyn, NY January 25, 2021 – Goalsetter, a Black-owned kids and family finance app that provides a next-generation, education-first banking experience for U.S. kids and teens, today announced its seed capital raise of $3.9 million. The capital raised will support the company’s plans to accelerate subscriber growth and enhance its ability to further build out its platform. Goalsetter is the only debit card in the U.S. with a financial literacy curriculum designed exclusively for teens and tweens.


Astia Appoints Larry Bettino as Chair of the Board Copy


Astia Appoints Larry Bettino as Chair Upon Retirement of Longtime Board Member Jamie Lerner

Veteran VC/PE investor with more than $1B in investment and private and public board experience to help lead Astia’s investment focus; replacing esteemed predecessor who served for nearly a decade.


RenovoRx Announces Issuance of Sixth U.S. Patent Copy


TIGeR-PaC — a Phase III Clinical Trial Continues Enrolling Pancreatic Cancer Patients in the U.S. and Europe


Shared sepsis / severe COVID-19 genetic risk factors with 59 potential drug re-purposing candidates identified in fight against COVID-19